Prices for the top 10 most popular U.S. pharmaceuticals have risen between 54 percent and 126 percent over the past five years. Six of the of the ten rose by nearly or more than double.
Drug (Brand Name) | Drugmaker | Conditions treated | Price per common dose | Price increase since 2011 | |
|---|---|---|---|---|---|
| 1 | Humira | Abbvie | Primarily treats arthiritis | $3,7973797 | 126%126 |
| 2 | Enbrel | Amgen | Primarily treats arthiritis | $932932 | 118%118 |
| 3 | Copaxone | Teva | Multiple sclerosis | $6,5936593 | 118%118 |
| 4 | Crestor | AstraZeneca | High cholesterol | $745745 | 113%113 |
| 5 | Abilify | Otsuka | Schizophrenia, bipolar disorder | $892892 | 96%96 |
| 6 | Lantus Solostar | Sanofi | Diabetes | $373373 | 94%94 |
| 7 | Advair Diskus | GlaxoSmithKline | Asthma | $335335 | 67%67 |
| 8 | Remicade | Johnson & Johnson | Primarily treats arthiritis | $1,0711071 | 63%63 |
| 9 | Neulasta | Amgen | Chemotherapy-related infections | $5,1565156 | 55%55 |
| 10 | Nexium | AstraZeneca | Primarily treats ulcers, acid reflux | $251251 | 54%54 |
